Drugs / Bifidobacterium lactis BB12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03032354 | Jul 2017 → Dec 2018 | type 1 diabetes mellitus | Medical University of Warsaw | Unknown | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium lactis Bb12 | “Lack of effect of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial.” PMID 33771763 ↗ Mar 2021 |
| Modality | Other / unclassified | “combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule” NCT03032354 ↗ |
| Route | Oral | “Children aged 8-17 years with newly (within 60 days) diagnosed T1D were enrolled in a double-blind, randomised controlled trial in which they received L. rhamnosus GG and B....” PMID 33771763 ↗ Mar 2021 |